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Serum levels of magnesium in sudden cardiac 
deaths among people with schizophrenia:  
hit or miss?
Níveis séricos de magnésio em morte súbita entre pessoas com esquizofrenia:  
erro ou acerto?
Fulvio A. Scorza1, Marly de Albuquerque1, Ricardo M. Arida2, Roberta Monterazzo Cysneiros3
Schizophrenia is a devastating mental disorder, affect-
ing cognitive, emotional, and behavioral conditions, ability 
to work, social functioning, family stability and self-esteem of 
the patient1,2. Furthermore, schizophrenia is a malignant con-
dition which has a high rate of premature death compared 
with the general population. Thus, people with schizophrenia 
show a two to three-fold increased risk to die prematurely 
than those without schizophrenia and this excess of mortality 
is accounted for by a combination of factors, such as patients’ 
life style, suicide (in particular in young male patients soon af-
ter diagnosis), premature development of cardiovascular dis-
ease, high prevalence of metabolic syndrome, carbohydrate 
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ABSTRACT
Schizophrenia is a devastating mental disorder, affecting cognitive, emotional, and behavioral conditions, ability to work, social functioning, 
family stability and self-esteem of the patient. People with schizophrenia show a two to three-fold increased risk to die prematurely than 
those without schizophrenia. Understanding the mechanisms behind sudden cardiac death in individuals with schizophrenia is a key to 
prevention. Although different mechanisms may be related, there are clear indications that cardiac abnormalities play a potential role. Some 
antipsychotics may be associated with cardiovascular adverse events, e.g., QT interval prolongation, metabolic dysfunction, blood pressure 
and heart rate alterations. Magnesium (Mg) abnormalities may lead to various morphological and functional dysfunctions of the heart and 
low levels of serum Mg are considered to be at high risk for sudden cardiac death. As low serum Mg is associated with detrimental effects 
on the heart and that antipsychotic-treated schizophrenia patients frequently affect the heart rate, possibly, these factors together must 
change the normal functioning of the heart and consequently being able to culminate in a catastrophic event.
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RESUMO
A esquizofrenia é uma doença mental que afeta as condições cognitivas, emocionais e comportamentais, a capacidade de trabalho, a esta-
bilidade familiar e social e a auto-estima do paciente. Pessoas com esquizofrenia apresentam um risco de duas a três vezes maior de morrer 
prematuramente em relação às pessoas sem esquizofrenia. A compreensão dos mecanismos envolvidos na morte súbita em indivíduos com 
esquizofrenia é de suma importância para sua prevenção. Apesar de diferentes mecanismos associados à doença, evidências mostram que 
as anormalidades cardíacas desempenham papel importante neste contexto. Alguns antipsicóticos podem estar associados com eventos 
cardiovasculares adversos, como o prolongamento do intervalo QT, disfunção metabólica e alterações na pressão arterial e no ritmo cardíaco. 
Anormalidades do magnésio (Mg) podem levar a várias alterações morfológicas e funcionais do coração assim como a um alto risco para a 
morte súbita. Como baixos níveis séricos de Mg estão associados a efeitos nocivos ao coração e indivíduos com esquizofrenia tratados com 
antipsicóticos frequentemente apresentam alteração do ritmo cardíaco, possivelmente, estes fatores em conjunto podem alterar o funcio-
namento normal do coração e, consequentemente, culminar em um evento catastrófico.
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and lipid metabolic disorders and, equally important but not 
so often mentioned, sudden cardiac death2-6. By definition, 
sudden cardiac death is a death from a cardiac cause within 
a short time (minutes to hours) after symptoms initially ap-
pear, often without warning2,7. In these lines, understanding 
the mechanisms behind sudden cardiac death in individuals 
with schizophrenia is a key to prevention. Probably, different 
mechanisms may be related in different cases; however, there 
are clear indications that cardiac abnormalities play a poten-
tial role6,8. In this regard, a number of considerations could 
be put forward to explain it. Firstly, it has been established 
that people with schizophrenia are at high risk for cardiovas-
cular disease, and some antipsychotics may be associated 
with cardiovascular adverse events (e.g., QT interval prolon-
gation), suggesting that this could lead to torsade the points 
or sudden death6,8-10. Second, the excellent review article by 
Ryan and Thakore11 suggests that schizophrenia and/or an-
tipsychotic agents are associated with metabolic dysfunc-
tion, including diabetes mellitus, increased triglyceride levels 
and weight gain, all of them known to be associated with in-
creased cardiovascular risk6,8,11,12. Third, it also been demon-
strated that antipsychotics frequently have effects on blood 
pressure and heart rate, among which orthostatic hypoten-
sion, with or without syncope, is relatively common8,13,14. 
Fourth, smoking is also considered an important risk factor 
for sudden cardiac death in schizophrenia patients2 and the 
effects of smoking may be due to an increase in platelet adhe-
siveness and release of cathecholamines2,15.
In face of these findings related above, the question arises 
as to whether sudden cardiac death in schizophrenia could be 
related to serum magnesium (Mg) levels? Before that, it is pru-
dent to us clarify our point of view. Recently, our research group 
demonstrated a typical case of sudden unexpected death in 
epilepsy (SUDEP), the leading cause of mortality in people 
with epilepsy, highlights a possible biomarker that may have 
triggered a fatal cardiac event in this individual with epilepsy 
i.e., low levels of serum Mg16,17. Accordingly, this proposal be-
came viable because it is well established in literature through 
experimental and clinical studies that Mg abnormalities may 
lead to various morphological and functional dysfunctions of 
the heart18 and more than that, low levels of serum Mg are con-
sidered to be at high risk for sudden cardiac death19,20. In this 
context, this line of scientific thought could be considered im-
portant to individuals with schizophrenia? Probably, yes.
For several years, the relationship between serum levels of 
Mg in people with schizophrenia has been shown discreetly in 
the literature. For example, Alexander et al.21, in 1978, studied 
serum Mg in drug-free and neuroleptic-treated schizophren-
ic patients. Although Mg was not significantly different in 31 
unmedicated schizophrenic patients compared with normal 
controls, people with schizophrenia treated with pimozide 
and fluphenazine (a structurally different neuroleptic drug) 
showed significant decreased in the  Mg levels when com-
pared with their drug-free values21. The following year, the 
same group evaluated the relationship between serum Mg 
level and neuroleptic-induced extrapyramidal symptoms 
(EPS) in schizophrenic patients. In brief, they found that Mg 
value was significantly lower at the onset of neuroleptic-in-
duced EPS than during the mean of an entire trial22. In paral-
lel, Athanassenas et al.23 studied serum Mg levels during neu-
roleptic treatment in a group of 29 chronic schizophrenic in 
patients who had previously remained drug free for at least 4 
weeks. The authors demonstrated a significant Mg decrease 
in the whole group during treatment and the magnitude of 
the decreased was independent of the neuroleptic used, sug-
gesting an interconnection between serum Mg changes and 
neuroleptic drug action23. Furthermore, Levine et al.24 mea-
sured cerebrospinal fluid levels of Mg in acute schizophrenics 
versus schizophrenic patients in remission and clearly dem-
onstrated that acute schizophrenics have significant lower 
levels of cerebrospinal fluid Mg.
To date, there are no reports in the literature on the rela-
tionship between low serum Mg and sudden cardiac death in 
schizophrenia. Thus, some considerations may be suggested 
on this new scientific approach. As low serum Mg is associ-
ated with detrimental effects on the heart and that antipsy-
chotic-treated schizophrenia patients per se frequently affect 
the heart rate it is very plausible to believe that these factors 
together must change “twice” the normal functioning of the 
heart and thereby, being able to culminate in a catastrophic 
event. On the whole, evidence for this proposition at present 
is minimal; however, new considerations and future studies 
should be evaluated to establish with precision the signifi-
cant of Mg dysfunction in schizophrenia field. In the mean 
time, caution with sudden cardiac death in schizophrenia 
continuous to be prudent and necessary.
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